Dr. Scott Gottlieb joins 'Fast Money' to talk how a Trump administration could impact the GLP-1 drug industry.

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

With deaths from obesity-related heart disease reportedly increasing by 180% over the past 20 years, more research is being done to learn how GLP-1 medications such as Ozempic, Wegovy, Mounjaro and ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

ANY SUBSTANTIAL CHANGE in your body weight, in either direction, will include a mix of fat and lean tissue. A steroid-free ...

GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives ...

More than 7 million Americans struggling with obesity would become eligible for coverage under the proposed change ...

The price of Wegovy, the diabetes control drug's glamorous anti-obesity sibling, may also be falling, according to a Health ...

Clinicians and patients should avoid using compounded GLP-1 products that are not FDA-approved, the American Diabetes Association wrote in a guidance statement published Dec. 2 in Diabetes Care. The ...